HIMS · Hims & Hers Health, Inc.
One customer — 10% of receivables (December 31, 2025)
“As of December 31, 2025, one customer or partner individually represented more than 10% of accounts receivable.”
4 customers — 10% of receivables (December 31, 2024)
“As of December 31, 2024, four customers or partners individually represented more than 10% of accounts receivable.”
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 104.6M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA margin non-GAAP | 8% | Six Months Ended June 30, 2026 | — |
| Free Cash Flow non-GAAP | -15.16M | Six Months Ended June 30, 2026 | — |
| Monthly Revenue per Average Subscriber | $92 | Three Months Ended June 30, 2026 | — |
| Subscribers (end of period) | 2.89M | Three Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HIMS
this stock
Hims & Hers Health, Inc.
|
$6.86B | -8.3% | +59.0% | — | 22.7% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +16.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -4.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.9% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -11.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HIMS | +4.9% | +4.8% | +50.8% | +0.7% | -8.3% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +5.6% | +4.6% | +38.7% | +1.3% | -20.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.